Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab Extension Study in Postmenopausal Women with Low BMD
NCT00325468Phase 3Completed
- Sponsor
- Amgen
- Start
- May 2006
- Primary completion
- Mar 2011
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 3, open-label, single-arm trial of denosumab in low bone mineral density, sponsored by Amgen. Primary endpoints: Lumbar Spine Bone Mineral Density Percent Change From Parent Study 20010223 Baseline to Year 8, Total Hip Bone Mineral Density Percent Change From Parent Study 20010223 Baseline to Year 8 and 1 more. Started May 2006; status: completed.
02
Drugs
denosumab
03
Conditions
low bone mineral density
Beyond the preview
Go deeper on NCT00325468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00325468.